<DOC>
	<DOCNO>NCT01301027</DOCNO>
	<brief_summary>This double blind randomized clinical trial pioglitazone vs. placebo overweight obese , diabetic non-diabetic hemodialysis patient . This study examine whether pioglitazone modulates adipokine production adipose tissue hemodialysis patient whether change result reduction inflammation , insulin resistance oxidative stress increase muscle mass . In addition , study also examine association adiposity adipokines metabolic milieu hemodialysis patient well understand biology adipocytes uremic milieu .</brief_summary>
	<brief_title>Effect Adipokines Hemodialysis Patients</brief_title>
	<detailed_description>Randomization : 100 overweight obese patient randomly allocate oral pioglitazone 15 mg/d placebo two week block five use random number generator monitor adverse event include hypoglycemia . If tolerate 15 mg pioglitazone match placebo two week , participant assign 30 mg pioglitazone match placebo 24 week . Those receive 15 mg pioglitazone receive 30 mg pioglitazone next 24 week . Those received placebo initial 2 week receive another placebo match 30 mg pioglitazone pill 24 week . Baseline : Participants fast blood drawn adipokines : Tumor Necrosis Factor-alpha ( TNF-alpha ) , Interleukin-6 ( IL-6 ) , high sensitivity C-Reactive Protein ( hsCRP ) , high molecular weight Adiponectin ( HMW-A ) , leptin . All patient undergo MRI scan mid-week non-dialysis day . Twenty overweight/obese patient randomize pioglitazone placebo also undergo subcutaneous fat biopsy mid-week non-dialysis day . Study Period : Participants return dialysis unit week 2 , 4 , 6 , 10 , 14 , 18 , 22 , 26 . During visit , clinical assessment conduct include review blood sugar , jaundice , weight gain , visual symptom . Study treatment compliance assess detail adverse event experience , particularly hospitalization emergency department visit collect . Fasting blood draw primary secondary outcome collect visit week 10 26 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Overweight ( Body Mass Index â‰¥ 25 kilogram per meter square ( kg/m2 ) ) Adult ( 18 year old ) Chronic hemodialysis patient Diabetic ( type 2 ) insulin resistant &lt; 18 year old No insulin resistance Active liver disease Class III IV New York Heart Association heart failure Macular edema hard exudate near macula fundoscopy Current active malignancy ( exclude squamous basal cell skin cancer ) Active AIDS Chronic lung disease require supplemental oxygen therapy Enrolled interventional trial use drug device Bone break long bone , vertebra , hip past three year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>End stage renal disease</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>Adipokines</keyword>
</DOC>